Experimental cancer drug NB004 trial halted early
NCT ID NCT05036291
First seen Apr 25, 2026 · Last updated May 23, 2026 · Updated 5 times
Summary
This early-stage study tested a new drug called NB004 in 25 adults with advanced solid tumors that had stopped responding to standard treatments. The main goals were to check safety and how the drug moves through the body. The trial was terminated early, so results are limited.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
LSU-LCMC Health Cancer Center
New Orleans, Louisiana, 70112, United States
-
National Cheng Kung University Hospital（NCKUH）
Tainan, Taiwan, 008866, China
-
National Taiwan University Hospital Yunlin Branch
Yunlin, Taiwan, 886, China
-
The University of Texas MD Anderson Cancer Center
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.